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Altered skeletal muscle ultrastructure in renal transplant patients on
prednisone. Treatment with glucocorticoids causes wasting of proximal
skeletal muscles. The purpose of the present investigation was to
quantify in the thigh muscle the areas of the different fiber types
determined by histochemical methods, and the muscle ultrastructure by
means of electron microscopy, in normal subjects (N = 41) and in renal
transplant patients treated with prednisone (N = 12). The cross—
sectional area of all three fiber types was reduced in renal transplant
patients treated with prednisone (10.6 4.3 mg/day), the fast glycolytic
fibers being most affected (slow oxidative fibers: 2642 625 vs. 3677
970 pm2, P < 0.001; fast oxidative fibers: 3275 735 vs. 4443 1343
pm2, P < 0.01; fast glycolytic fibers: 2305 802 vs. 3920 1522 /im2,
P < 0.001). This was mostly due to a decrease in the volume of
myofibrils per unit volume of muscle fiber (—30%). The intracellular
lipid content and the volume density of subsarcolemmal mitochondria
were increased by moi-e than 70% in prednisone treated patients. In
conclusion, the decreased myofibril areas might account for the muscle
weakness in renal transplant patients treated with prednisone, and the
decrease in myofibrils is in part functionally compensated by an
increase in subsarcolemmal mitochondria and intracellular lipid con-
tent.
The development of muscle weakness and atrophy is a well
known complication of therapy with exogenous glucocorticoids
and Cushing's disease [1, 2]. It is probably the most common
form of drug induced myopathy encountered in clinical practice
[31. We have recently shown that mid-thigh muscle area as-
sessed by computed tomography methods and thigh muscle
strength are concomitantly decreased in glucocorticoid—treated
renal transplant patients [4]. In animals, chronic glucocorticoid
treatment results in an atrophy affecting predominantly type II
B ("fast glycolytic") fibers, whereas type I ("slow oxidative")
fibers and type II A ("fast oxidative") fibers are said to he less
affected [5—8]. In man, an atrophy of type TI, and to a lesser
extent of type I, fibers has also been described in patients
treated with glucocorticoids [9, 101 and Cushing's disease [10].
Systematic quantitative analysis of the ultrastructure of skeletal
muscles so far are not available in patients treated with
glucocorticoids. Therefore, the purpose of the present investi-
gation was to quantify in the thigh muscle the fiber cross—
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sectional areas of the three fiber types by histochemical meth-
ods, and muscle ultrastructure by morphometry, in normal
subjects and in renal transplant patients treated with glucocor-
ticoids.
Methods
Patients and normal subjects
Twelve, clinically stable renal transplant patients (six
women, six men) were studied. The patients' characteristics
were: age 35 8 (SD) years, body height 165 10 cm, body
weight 63 10kg, and body mass index 23.1 0.7 kg/rn2. The
reasons for terminal renal insufficiency were: glomerulonephri•-
tis (seven patients), analgesic nephropathy (two), reflux ne-
phropathy (two) and polycystic kidney disease (one). Prior to
transplantation they had been on long—term dialysis for 3 to 158
months (median 16 months). Before renal transplantation, ten-
don reflexes of the lower extremity were normal and no sensory
loss of the legs was observed. All had been transplanted at least
eight months prior to the investigation (4.0 2.7 years). No
patients with aseptic necrosis of the femoral head or with joint
diseases of the lower extremities were included. All patients
were rehabilitated in that, after renal transplantation, they had
resumed their professional and private activities. Prednisone
was administered to all patients (actual dose 10.6 4.3 mg/day;
mean dose for the last three months before the investigation:
10.8 4.9 mg/day; mean dose for the last year: 11.7 5.2
mg/day). Plasma creatinine was 133 50 mmol/liter (1.5 0.6
mg%). Calcium concentrations in plasma and alkaline phospha-
tase were within the normal range. In addition the patients were
receiving azathioprine (11 patients), cyclosporine (one) and
various other drugs such as furosemide, calcium antagonists
and beta—adrenergic antagonist agents.
For comparison 41 individuals (32 men, nine women), admit-
ted to the orthopedic surgery department because of chronic
unilateral knee instability, were studied. None of them had any
clinical or routine laboratory evidence of renal disease and none
of them had been treated with sytemic or intraarticular gluco-
corticoids or with immunosuppressive drugs. Their character-
istics were: age 30 eight years, body height 174 7cm, body
weight 73 13 kg, and body mass index 24.1 2.1 kg/rn2. The
biopsy was taken from the vastus lateralis muscle of the healthy
unaffected leg prior to the operation.
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Fig. 1. EM of a mid-thigh biopsy at a magnification x 530. A normal subject is (A), A renal transplant patient treated with prednisone is (B). Note
the reduced fiber area (F) of the patient treated with prednisone. Symbol is capillaries.
All subjects gave informed consent. The protocol was ap-
proved by the Committee on Human Research at our Institu-
tions.
Muscle biopsy and fixation
The biopsy was taken from yastus lateralis muscle at mid-
thigh level using the teehinque of Bergstrom [11]. A large
fraction of the muscle tissue sample taken from each subject
was immediately frozen in isopentane, cooled in liquid nitrogen,
and processed for histochemistry [12, 131. The remainder of the
muscle tissue samples were processed for electron microscopy
by fixation in a 6.25% solution of glutaraldehyde as previously
described [14].
Histochemical analysis
Serial transverse sections (10 m) were cut from biopsies at
—30°C on a cryostat microtome and placed on glass slides for
histochemistry as described previously [12, 131. Histochemistry
consisted of assaying for myofibrillar actomyosin ATPase ac-
tivity following an acid and alkaline preincubations (pH 4.40;
4.60; 4.67 and 10.4). All sections were incubated for 20 minutes
in a medium containing 40 mmol glycinc, 20 mmol CaCI2 and 5
mmol AlP (pH 9.4). The fibers were classified into fiber types
I, II A, II B according to Brooke and Kaiser [12]. On average,
583 242 fibers were counted from each biopsy. Fiber typing
was done by a person unaware of the identity of the muscle
sample. Fiber type distribution was estimated at a final magni-
fication of x 200 and with a A 100 grid (100 test points) using
standard sterological procedures [15]. On each slide, sampling
for histochemistry was done systematically with a random
starting point (rnicrographs not overlapping).
Electron microscopy (EM) and morphometry
Two randomly—chosen blocks from each biopsy were used
for the sterological analysis. The orientation of the sections was
transverse with regard to muscle fiber axis (Fig. 1). Eight
micrographs per block and hence 16 micrographs per biopsy
were taken in consecutive frames of slotted grids (type R 100 A,
Vecocompany, Holland), yielding more than 100 muscle fiber
profiles for analysis in each biopsy. Capillary number, fiber
number and fiber cross—sectional area were estimated at a final
magnification of x 1500 as previously described [16, Fig. 11. A
final magnification of X 24,000 was used for estimation of
volumes of mitochondria, intracellular lipids and myofibrils per
volume of muscle fibers (Fig. 2). Twenty rnicrographs per block
and hence 40 micrographs per biopsy were taken with a
systematic sampling procedure in consecutive frames of 200-
square mesh grids. Contact prints of the 35 mm films were
projected on a screen fitted with quadratic line grids. Point
counting was performed with an A 100 grid (100 test points) for
the low magnification and with a B 36 grid (144 test points) for
the high magnification [141. Parameter estimates were obtained
according to standard sterological procedures [15]. Since most
of the histochemical sections were cut fairly oblique, fiber areas




a (f, histo) = a (f, EM) ; units: m2
NN (hsto)
where a (f, EM) is the average fiber cross—sectional area
obtained through EM-morphometry, and V (histo) and NN
(histo) arc the volume and numerical densities of muscle fiber
types obtained from histochemistry, respectively, a (f, histo) is
I 
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Fig. 2. EM of a midt high biopsy at a magnification x 17120 of a nor,nal subject (A) and of a renal transplant patient treated with prednisone (B).
Note the increased intraceflular lipid content (L) and the accumulation of subsarcolemmal mitochondria (M) in the patient treated with prednisone
(B). Abbreviation (G) is Glycogens.
an unbiased estimate of the fiber cross—sectional area of any of
the three fiber types, as both Vj (histo) and NN (histo) are not
dependent on sectioning angle.
Statistical analysis
The sterological study was designed to yield the estimated
mean of volume of mitochondria with a standard error of
approximately 10% [171. Comparisons were done using the
unpaired Student's (-test.
Results
Histochemical inorphometry of fiber areas
All three fiber types showed lower mean fiber areas by more
than 25% in renal transplant patients treated with prednisone as
compared to normal subjects (Table 1). The reduction in fiber
area was more pronounced in type II B fibers than in type I and
type II A fibers, This is also shown by the fact that the ratio of
1/Il A areas was not different between patients and normal
subjects, whereas the ratios of I/IT B and II A/Il B areas were
significantly higher in patients treated with prednisone than in
normal subjects (Table 1).
Ultrastructural morphometry
Fiber cross—sectional area and dia,neter. Mean fiber cross
sectional area was reduced by more than 27% in renal trans-
plant patients (Table 2). Consequently, fiber diameters were
decreased and fiber number/mm2 was higher by 34% in predni-
sone treated renal transplant patients, when compared with
normal subjects (Table 2),
Table 1. Fiber areas of vastus lateralis muscle in normal subjects and







Type 11 A, pm2










Ratio of fiber areas
I/TI A 0.85 0.18 0.82 0.13 NS
1/11 B 1.00 0.27 1.27 0.50 < 0.02
11 A/lI B 1.17 0.19 1.56 0.55 < 0.001
All values are given as mean SD.
Volume density of intracellular ultrastructures (Table 2).
Mean volume of subsarcolemmal mitochondria was higher by
more than 90% in patients, whereas volume density of interfi-
brillar mitochondria remained unchanged. As subsarcolemmal
mitochondria only represent 10% of the total mitochondria in
controls, the large change in subsarcolemmal mitochondria did
not affect the total mitochondrial volume to a significant degree.
The volume fraction of intracellular lipid deposits was signifi-
cantly increased by 70% and the volume fraction of residual
sarcoplasmatic components (glycogen, sarcoplasmatic reticu-
lum, Golgi apparatus, nucleus) by 19%. The latter increase was
mainly due to an increase in glycogen in prednisone treated
patients. Without morphometric methods, this difference can
hardly be visualized in Fig. 2 because the difference in volume
414 IIo,her et al
Table 2. Electron microscopy morphometry of vastus lateralis








cross sectional area, jun2 3932 1018 2871 623 < 0.002
diameter, j,m 70.2 8.9 60.1 6.5 < 0.001
number/mm2 271 69 364 78 <0.001
Volume density of
intracellular structure
4.13 0.87 4.45 1.31 NSmitochondria, total
mitochondria, interfibrillar 3.68 0.72 3.61 0.96 NS
mitochondria, subsarcolemmal 0.44 0.27 0.84 0.51 < 0.001
intracellular lipids 0.46 0.37 0.79 0.50 < 0.05
myofibrils 82.3 2.3 78.9 3.4 < 0.001
residual structures 13.2 1.9 15.7 2.4 < 0.001
Capillary number
per fiber number 1.54 0.39 0.99 0.27 < 0.001
per fiber area, mm2 407 105 347 63 NS
All values given as mean SD.
density of the residual structures between patients and normal
subjects was only 2.5% (Table 2).
We found a significant decrease in the volume fraction of
myofibrils representing more than 80% of the total cell volume
in controls. The mean cross sectional area of myofibrils per
fiber area (mean volume density of myofibrils times mean fiber
cross sectional area, tm2) was lower in patients treated with
prednisonc than in the normal subjects (2254 438 m2 vs.
3234 847 m2, P < 0.001).
Capillaries
Mean capillary to fiber ratio was reduced in prednisone
treated patients by more than 30% compared with normal
subjects, while the ratio of capillary number to fiber area was
not different in the two populations investigated (Table 2).
Qualitative histological analysis f the biopsies
in renal transplant patients, no fiber group atrophy was
detected. in addition, typical histological myopathic signs (in.
creased number of central nuclei, myclin figures, autophagic
vacuoles, disrupted filaments and increased lipofuszin [l822])
were not observed in the biopsies from the patients treated with
prednisone.
Discussion
To our knowledge, the present investigation shows for the
first time quantitative morphometric data on skeletal muscle
ultrastructure in humans treated with glucocorticoids for pro-
longed periods of time. Renal transplant patients were chosen
as a patient population because their glucocorticoid treatment is
preventive in nature; they take prednisone to prevent a renal
transplant rejection. All other patient populations receive glu-
eocorticojds in order to treat an actual disease state. Therefore,
in these patient populations, the influence of prednisone on
muscle ultrastructure could be confounded by the underlying
disease.
The drawback of studying renal transplant patients on pred-
nisone is the preexisting renal failure. For the following four
reasons the changes in muscle structure in our patient popula-
tion were mostly due to glucocorticoid treatment rather than to
the anamnestic uremia. I) Our patients were successfully trans-
planted eight months to 105 months (median 35 months) prior to
the present investigation and their nutritional habits and phys-
ical activities had been normalized for a long time period. 2)
There are several reports about muscle histology in uremic
patients (18—22). In most of the histologically analyzed biopsies
from uremic patients, typical myopathic changes—not present
in our patients treated with prednisone—could be detected
(increased number of central nuclei of muscles fibers [18, 19, 21,
221, myelin figures [19, 20, 22], autophagic vacuoles [19],
disrupted filaments [18, 19, 22], and increased lipofuszin [18,
22]), 3) Group atrophy of muscle fibers suggesting neuropathy
was also described in uremie patients [21, 22], in our 12 renal
transplant patients treated with prednisonc, no such qualitative
neuropathic histological signs could be detected. 4) The total
muscle fiber content of mitoehondria in uremic patients was
reported to he more than 100% higher than in normal volunteers
[22]. Our patients treated with prednisone did not exhibit such
an uremia—associated, increased total mitochondria content of
the muscle fibers (Table 2), indicating that the muscle changes
observed in our patients were due to administration of glueo-
corticoids rather than to the anamnestic uremia.
The principal effect of glucocorticoids, which can be linked to
the basic action of glucocorticoids on muscle cells, appears to
be an inhibition of protein synthesis [23, 24]. This decreased
protein synthesis results in lowered mid-thigh muscle areas as
we have recently demonstrated by computed tomography meth-
ods [25]. The present study shows that glucocorticoid treatment
causes a lower volume of myofibrils per unit volume of muscle
fiber. Thus, the reduced mid-thigh muscle area, in combination
with the decreased volume density of myofibrils, can explain
the observed weakness of the thigh muscles in glueoeorticoid
treated patients [4, 25]. From the currently available data, it can
be calculated that the total loss of contractile proteins from
thigh musculature must be on the average 30% in pred-
nisone—treated, renal transplant patients as compared to normal
subjects.
Glucocorticoid treatment induces a mixed muscle fiber atro-
phy with a predominance of type Ii fibers in experimental
animals [5—8]. Recently, Khaleeli et al [91 reported in humans
that in addition, steroid myopathy might be associated with a
reduction in type 1 fiber size, These authors observed reduced
mean type 1 fiber areas in two out of three patients treated with
prednisone (7.5 to 10 mg/day). The present investigation con-
firms this finding in a larger patient population treated with
prednisone. Only in two out of seven patients with (endoge-
nous) Cushing's disease an atrophy of type I fibers has previ-
ously been reported [9, 10]. Thus, at the present time, one
cannot establish unambiguously in man whether the type I fiber
atrophy in patients treated with exogenous glucocorticoids is
due to the excess of glucocorticoids or to the underlying
disease. The concept that glucocorticoids directly cause a type
I fiber atrophy is supported by animal studies [6, 8]. Gardiner et
al observed an atrophy of type I fibers in cat quadriceps muscle
when animals were treated with glucocorticoids [6].
in our patient population treated with prednisone, the type II
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B fiber area was reduced to a greater extent than the areas of the
type II A or type I fibers. The increased sensitivity of type II B
fibers to glucocorticoid treatment has previously been demon-
strated in animals [6, 8], while in man only a diminished type II
fiber area without specifying which subtype was reduced, has
been reported in a total of nine patients treated with
glucocorticoids [9, 10, 26]. The basis of the selective suscepti-
bility of the fast twitch glycolytic type II B fibers in man is not
clear. Differences in glucocorticoid receptor content between
the different fiber subtypes seem not to be a valid explanation
[27, 28]. An alternative explanation might be that the influence
of glucocorticoids on the activity of some metabolic key en-
zymes might be different in the three fiber subtypes. The
metabolism of type II B fibers depends heavily upon glycolysis,
while type I and type II A have a greater oxidative capacity.
Kerppola showed that glucocorticoids inhibit the phosphory-
lase activity and increase glycogen content in muscles of rabbits
[29]. Thus, it is conceivable that the increased storage of
glycogen might indicate a decreased availability of glucose for
the anaerobic metabolism in type II B fibers.
In the 1960s, qualitative ultrastructural analyses of mito-
chondria have been performed in muscle cells of patients
treated with glucocorticoids. These analyses revealed numer-
ous alterations of mitochondria such as "enlargement", "ag-
gregation" or "vacuolation" [26, 30, 31]. In the present inves-
tigation we could not find any qualitative structural abnormal-
ities of mitochondria. Whether this discrepancy is explained by
patient selection or the techniques used for the sample prepa-
ration for the electron microscopy is unknown. In uremic
patients abnormal mitochondria were often observed [221. In
addition, in these patients total volume of mitochondria were
increased by more than 100% [22], whereas in our patient
population treated with prednisone, only the subsarcolemmal
fraction of mitochondria was increased (Table 2). This finding is
consistent with the increased subsarcolemmal mitochondria of
the quadriceps muscle observed by Walsh in hydrocortisone
treated rats [81 and by Engel in one patient treated with
prednisone [26]. Subsarcolemmal mitochondria are localized in
the periphery of muscle fibers. Teleologically this might be an
advantage due to their proximity to the capillary network.
There is evidence that following the administration of glucocor-
ticoids the glycolytic metabolism of skeletal muscle is impaired
(29), while the oxidative metabolism which occurs predomi-
nantly in the mitochondria is increased [32]. Thus, one might
speculate whether the increase in the subsarcolemmal mitochon-
dna represents an adaptive mechanism in prednisone treated
patients. Note that a similar increase in the content of
subsarcolemmal mitochondria has been observed by our group
in normal volunteers after an endurance training, which is
believed to enhance oxidative metabolism in muscle cells [161.
Treatment with glucocorticoids increases adipose tissue,
especially in the truncular region [33—35]. The present investi-
gation demonstrates that in addition, the intracellular lipid
content of muscle cells is increased in patients treated with
prednisone. Interestingly, a similarly increased intracellular
lipid content has been observed in muscle cells after endurance
training [16, 36]. From studies in normal volunteers it is known
that the higher intracellular lipid content is usually combined
with higher activities of enzymes involved in the /3-oxidation of
free fatty acids, and it was suggested that increased endurance
is partly explained by a more important utilization of lipids as a
substrate in energy metabolism [37]. In patients treated with
prednisonc, an increased utilization of lipids as an energy
source might be of importance in the light of their impaired
glycolytic metabolism. Shah et al [22] have observed an in-
crease in intracellular lipid content by more than 400% in
uremic patients. This increased intracellular lipid content was
explained by a loss of intramuscular carnitine while the patients
were on dialysis [201. Further studies are needed to establish
whether the increased intracellular lipid content in renal trans-
plant patients is due to the administration of exogenous gluco-
corticoids or to a preexisting uremic carnitine deficiency.
Interestingly, patients treated with prednisone for reasons other
than renal transplantation showed decreased muscle density
measured by computed tomography, suggesting an increased
muscular lipid content [35].
In conclusion, renal transplant patients treated with predni-
sone have a decreased average muscle fiber cross—sectional
area. Muscle fibers of type I and II A are less affected than
fibers of type II B. In addition, the volume density of myofibrils
is decreased. These combined findings might explain the de-
creased muscular strength in patients treated with prednisone.
Muscle cells from patients on prednisone show an increased
volume of subsarcolemmal mitochondria and an increased
intracellular lipid content when compared to muscle cells
obtained from normal untrained subjects. Such an increase in
lipid content and subsarcolemmal mitochondria volume is usu-
ally found in normal subjects after an endurance training. Thus,
it might be speculated that the usual daily physical activity in
the presence of the prednisone—induced, decreased functional
muscle mass causes an adaptive response in patients treated
with glucocorticoids which is similar to the one that is usually
observed in normal subjects after a strenuous endurance train-
ing program.
Acknowledgments
We acknowledge the assistance of Dr. FT. Herren and Mrs. C. Weder.
Grant support for this study is from the Swiss National Foundation for
Scientific Research (No. 3.914-0.82).
Reprint requests to FelixJ. Frey, M.D., tvfedizinische Poliklinik, 3010
Bern, Switzerland.
References
I. MOu R, KUGELBERG E: Myopathy in Cushing's syndrome. J.
Neurolog Neurosurg Psychiatry 22:314—317, 1959
2. PERKOFF GT, SILBER R, TYPLER FH, CARTwRIGHT GE,
WINTROBE MM: Studies in disorders of muscle: Xli. Myopathy due
to the administration of therapeutic amount of 17-hydroxy cortico-
steroids. Am J Med 26:891—896. 1959
3. MASTAGLIA FL: Adverse effect of drugs on muscle. Drugs
24:304—321, 1982
4. HORBER FF, SCHEIDEGGER JR, GRONIG BE, FREY FJ: Evidence,
that prednisone—induced myopathy is reversed by physical training.
J Clin Endocrinol Metal 61:83—87, 1985
5. LIVINGSTONE 1, JOHNSON MA, MASTAGLIA FL: Effects of dexa-
methasone on fibre subtypes in rat muscle, J Neuropathol and AppI
Neurobiol 7:381—398, 1981
6. GARDINER PF, BOTTERMAN BR, ELDRED F, SIMPSON DR.
EDGERTON VR: Metabolic and contractile changes in fast and slow
muscles of the Cat after glucocorticoid—induced atrophy. Exp
Neurol 62:241—255, 1978
7. SMITH B: Histological and histochelnical changes in the muscles of
416 LIorber et a!
rabbits given the corticosteroid triarneinolone Neurology
14:857—863, 1964
8. WALSH G, DE Vivo D, OLSON W: Histochemical and ultrastruc-
tural changes in rat muscle. Occurrence following adrenal
corticotrophic hormone, glucocorticoids and starvation. Arch
Neurol 24:83—93, 1971
9. KHALELLI AA, EDWARDS RHT, G0HIL K, McPHAIL 0, RENNIE
Mi, ROUND J, Ross EJ: Corticosteroid myopathy: A clinical and
pathological study. C/in Endocrinol 18:155—161, 1983
10. PLEASURE DE, WALSH GO, ENGEL WK: Atrophy of skeletal
muscle in patients with Cushing's syndrome. Arch Neurol
22:118—125. 1970
Ii. BERGSTRUOM I: Muscle electrolytes in man. Scand J C/in Lab
Invest 14 (Suppl. 68):11—12, 1962
12. BlooKE MI-I, KAISER KK: 1970 Muscle fiber types: How many and
what kind? Arch Neuro! 23:369—379, 1970
13. PADYKULA HA, HERMAN E: Factors affecting the activity of
adenosine triphosphatase and other phosphatases as measured by
histochemical techniques. J Histochem C'ytochem 3:170—195, 1955
14. HOPPELER H, LUTHI P, CLAASSEN H, WEIUEL ER, HOWALD H:
The ultrastructure of the normal human skeletal muscle. A mor-
phometric analysis on untrained men, women and well—trained
orienteers. Jfldgers Arch 344:217—232, 1973
IS. WEIBEL ER: Practical methods for biological morphometry, in
Stereoiogica/ methods. London, New York, Toronto, Academic
Press, 1979
16. HOWALD H, HOPPELER H, CLAASSEN H, MATHIEU 0, STRAUB R:
Influences of endurance training on the ultrastructural composition
of the different muscle fiber types in humans. Pf/igers Arch
403:369—378, 1985
17. MATHIEU 0, CRuz—ORIvE LM, 1-IOPPELER H, WEIBEL ER: Mea-
surmg error and sampling variation in sterology: Comparison of the
efficiency of various methods for planar image analysis. J Micro.sc
121:75—88, 1981
18. BUNDSCHU HO, SCHLOTE W: Elektronenmikroskopische lJnter-
suchungen der Skelettmuskulatur bei terminaler Niereninsuf-
fizienz. J Neurosurg Sci 23:243, 1974
19. FLOYD M, AYYAR OR, BARWICK DD, HUDGSON P, WEIGUTMAN
D: Myopathy in chronic renal failure. Q J Med 172:509, 1974
20. BELLINGHIERI G, SAVICA V, MALLAMACE A, Di STEFANO C,
CoNsoLo F, SPAGNOLI LG, VILLASCHI S, PAt MIERI 0, Cosi M,
MACCARl F: Correlation between increased serum and tissue L-
carnitine levels and improved muscle symptoms in hemodialyzed
patients. Am J C/in Nuir 38:523, 1983
21. AHONEN RE: Light microscopic study of striated muscle in uremia.
Acta Neuropathol 49:51, 1980
22. SHAH AJ, SAHGAL V, QUINTANILLA AP, SLJIIRAMANI V, SINGH H,
HUGHES R: Muscle in chronic uremia—a histochemical and moe-
phometric study of human quadriceps muscle biopsies. C/in Neu-
roparho/ 2:83, 1983
23. KELLY FJ, GOLDSPINK OF: The differing responses of four muscle
types to dexamethasone treatment in the rat. Biochem J
208:147—158, 1982
24. SH0.Ji S, PENNINGTON RJT: The effect of cortisone on protein
breakdown and synthesis in rat skeletal muscle. Mo! Ce/I Endocri-
no! 6:159—169, 1977
25. HORBER FF, SCHEIDEGGER JR, GRUNIG BE, FREY Fi: Thigh
muscle mass and function in patients treated with glucocorticoids.
Europ J C/in Invest (in press)
26. ENGEL AG: Electron microscopic observations in thyrotoxic and
corticosteroid—induced myopathies. Mayo C/in Proc 41:785—796,
1966
27. SHOJI S, PENNINGTON RJT: Binding of dexamethasone and cortisol
to cytosol receptors in rat extensor digitorum longus and soleus
muscles. Exp Neurol 57: 342—348, 1977
28. SAARFOK T: Steroid receptors in two types of rabbit skeletal
muscle. hit J Sport Med 5:130—136, 1984
29. KERPPOLA W: Inhibition of phosphorylase with cortisone and its
activation with adrenaline in the rabbit. Endocrino/ogy 51:192—202,
1952
30. Ann AK, BERGMAN RA, HARVEY JC: Steroid myopathy. Clinical,
histologic and cytologic observations. John Hopkins Med J
123:158—174, 1968
31. GOLDING ON, MURRAY SM, PEARCE OW, THOMPSON M: Cortico-
steroid myopathy. Ann Phys Med 6:171—179, 1961
32. VinNos, P, GREENE R: Oxidative respiration of skeletal muscle in
experimental corticosteroid myopathy. fLab C/in Med 81:365—377,
1973
33. MELBY JC: Systemic corticosteroid therapy: Pharmacology and
endocrinologic considerations. Ann mt Med 8 1:505—509, 1974
34. AXELROD 1.: Glucocorticoid therapy. Medb.'ine 55:39—44, 1976
35. HORBER FF, ZORCHF,R RM, CRIVELLI MA, ROBOTTI G, FREY F.!:
Altered body fat distribution in patients with glucocorticoid treat-
ment and in patients on long—term dialysis. Am J C/in Nutr (in
press)
36. HOPPELER H, HOWALD H, CONLF,Y K, LINDSTEDT SL, CLAA55EN
H, VOCK P. WEIBEL ER: Endurance training in humans: Aerobic
capacity and structure of skeletal muscle. J App! Physio/ (in press)
37. MOESCH H, HowAI,1 H: Hexokinase (HK), Glyeraldehyde-3p-
Dehydrogenase (GAPDH), Succinate—Dehydrogenase (SDH) and
3-Hydroxyacyl-CoA-Dehydrogenase (HAD) in skeletal muscle of
trained and untrained men, in Metabolic adnptation to pro/onged
exercise, edited by HOWALD H, POORTMANS, J Base!, Birkäuser,
1975, p. 463
